Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004163 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00004163 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants.
The verdict
NCT00004163, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have advanced salivary gland cancer.
Interventions
- DRUG Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 1999-10 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004163
The ClinicalTrials.gov registry entry for NCT00004163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trastuzumab is the first listed.
NCT00004163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004163 about?
NCT00004163 is a clinical study titled "Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer". RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have advanced salivary gland cancer...
What is the current status of trial NCT00004163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 1999-10. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00004163?
The interventions under investigation include: Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT00004163?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.